Neurol. praxi. 2011;12(6):430-433
Correlation of MхA mRNA expression with NAbs levels in patients with multiple sclerosis
- 1 OKBHI, Nemocnice Na Homolce, Praha
- 2 Neurologická klinika 2. LF a FN Motol, Praha
- 3 Ústav lékařské mikrobiologie 2. LF a FN Motol, Praha
Myxovirus resistance protein A (MxA) belongs to dynamin superfamily. MxA is a component of antiviral response and is solely induced
by interferons, thus by in vivo application of interferon β (INFβ) as well. In patients with multiple sclerosis (MS), neutralizing antibodies
(NAbs) appearing during INFβ treatment in 10–30 % of cases, decrease its bioactivity and therapeutic efficacy. The aim of this study was
to show the correlation of MxA and Nabs levels on the cohort with relaps-remitting form of MS (RR-MS) and to set up the cutoff value for
the baseline levels of MxA in population. The cohort sustained of 16 NAbs positive, 43 NAbs negative patients and 105 negative controls.
This study demonstrates high correlation in high NAbs levels and depletion of MxA expression. The cutoff MxA/GAPDH (baseline) value
was assigned as a 95 percentile of values of negative controls: MxA/GAPDH = 160.
Keywords: MxA, multiple sclerosis, interferon, NABs
Published: December 1, 2011 Show citation
References
- Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT. Evaluation of bioavailability of three types of IFN? in multiple sclerosis patiens by a new quantitative-competitive-PCR method for MxA quantification. J. Immunol. Methods 256 1-2 2001: 141-152.
Go to original source... 
Go to PubMed... - Hesse D, Sellebjerg F, Soelberg Sorensen P. Absence of MxA induction by interferon 2 in patients with MS reflects complete loss of bioactivity Neurology 2009; 73: 372-377. Go to original source... Go to PubMed...
- Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology. 2000; 54: 2055-2060. Go to original source... Go to PubMed...
- Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, Bertolotto A. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 2006; 12: 47-57. Go to original source... Go to PubMed...
- Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A. Biological responsiveness to first injection of interferon -beta in patiens with multiple sclerosis. J Neuroimmunol 2005; 158: 195-203. Go to original source... Go to PubMed...
- Gilli F, Marnetto F, Stefanuto G, Rinaldi V, Farinazzo F, Malucchi S, Capobianco M, Caldano M, Sala A, Bertolotto A. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Mol Diagn 2004; 8: 185-194. Go to original source... Go to PubMed...
- INF beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: clinical results of a multi-center, randomised, double-blind, placebocontrolled trial. Neurology 1993; 43: 655-661. Go to original source... Go to PubMed...
- Kracke A, von Wussov P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology. 2000; 54: 193-199. Go to original source... Go to PubMed...
- Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFN? bioactivity: monitoring in MS patients and the effect of anti-IFN? antibodies. J Neuroimmunol 2005; 166: 180-188. Go to original source... Go to PubMed...
- Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 2006; 66: 444-446. Go to original source... Go to PubMed...
- Pachner AR, Narayan K, Price N, Hurd M, Dail D. MxA gene expression analysis as an interferon-? bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity. Mol Diagn 2003; 7: 17-25. Go to original source... Go to PubMed...
- PRISMS (Prevention of Relapses and Disability by Interferon ß-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504. Go to original source...
- PRISMS (Prevention of Relapses and Disability by Interferon ß-1a Subcutaneously in Multiple Sclerosis) Study Group and University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001; 56: 1628-1636. Go to PubMed...
- Pungor E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL, Nelson JW, Nestaas E, Taylor JL, Grossberg SE. A novel bioassay for the determination of neutralizing antibodies to IFNb1b. J Interferon Cytokine Res 1998; 18: 1025-1030. Go to original source... Go to PubMed...